Results  1 - 20 of 25

View all
< Prev
Date Topic
3/4/2012G20 anti-bribery inconsistencies raise challenges and costs for international businesses
28/3/2012Freshfields names 20 new partners
23/1/2012Freshfields advises Roche Diagnostics on manufacturing and supply agreement with Altek
9/1/2012Freshfields advises on first UK PFI monoline replacement
3/10/2011Freshfields advises Capita Asset Services as special servicer of the lenders to NHP in connection with the restructuring of Southern Cross Healthcare Group PLC
26/5/2011News release - Freshfields advises AB Sanitas on Valeant Pharmaceuticals sale for €314m
23/5/2011Freshfields advises on sale of Russian/CIS pharma assets to Johnson & Johnson
19/5/2011Freshfields advises on 9.6bn Euro private equity pharma deal
19/5/2011Freshfields advises Cinven on $3.5bn disposal of Phadia
4/4/2011More than half of the UK’s largest companies welcome scrapping the default retirement age but almost two thirds fear potential damage to economic recovery and job creation
28/2/2011Freshfields appoints global CMO
13/1/2011Freshfields tops M&A league tables for 2010
10/1/2011Freshfields appoints new regional managing partner for Asia
10/1/2011Freshfields advises Merck KGaA on the sale of Théramex to Teva
23/12/2010EU Cartel settlements near record with more than €3 billion in penalties delivered in 2010
20/12/2010Cross-border acquisitions by UK companies reach highest share in 10 years
17/12/2010Europe proves valuable hunting ground for US bribery investigations with nearly $1.5 billion in penalties collected from EU companies this year
19/10/2010Widespread industrial action across the private sector is unlikely, according to Freshfields Bruckhaus Deringer
30/9/2010Freshfields elects new international leadership team
6/8/2010Fewer corporate insolvencies but company voluntary arrangements rise by almost 50% and real estate and construction account for more than half of larger cases

News

G20 anti-bribery inconsistencies raise challenges and costs for international businesses View

Freshfields names 20 new partners View

Briefings

Life sciences: China  View

Class actions in the EU: a threat to the life sciences industry?  View

Contact